在中度活性的性结肠炎中,将脉冲皮质类固醇添加到口服普雷尼松中:GETECCU的一项随机,多中心,开放的标签研究
Jordina Llaó1,2, Míriam Mañosa1,3, Eduardo Martín-Arranz4
1Gastroenterology & Hepatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Journal of Crohn's & colitis
|November 19, 2025
概括
在服用口服皮质类固醇之前添加高剂量的甲基前尼索隆脉冲并没有改善中度活性的性结肠炎 (UC) 的缓解率. 这项研究发现,治疗组之间的无类固醇缓解没有显著差异.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
- 免疫抑制是一种免疫抑制.
背景情况:
- 口服皮质类固醇是中度活性的性结肠炎 (UC) 的标准治疗方法,30%-60%的患者实现了缓解.
- 优化初始皮质类固醇治疗对于改善UC患者的治疗结果至关重要.
研究的目的:
- 为了比较无类固醇的临床内镜缓解率在8周和54周.
- 为了评估在中度活跃的UC患者口服皮质类固醇之前添加3个甲基-普雷迪尼索隆脉冲的疗效.
主要方法:
- 一个前性的,开放的,多中心的,随机对照试验.
- 患者接受了传统的治疗 (CT) 用口服普雷尼松或CT前3天静脉注射甲基-普雷尼索隆脉冲.
- 患者被跟踪12个月或直到临床复发.
主要成果:
- 在传统治疗 (23%) 和额外脉冲 (33%) 组 (P=0.323) 之间,在8周和54周临床内镜缓解没有显著差异.
- 额外脉冲组在第3天显示出更高的临床反应率,并在第7天显示出更高的缓解率.
- 该研究由于早期终止而不足,研究结果被认为是探索性的.
结论:
- 添加3个高剂量的甲基-普雷尼索隆脉冲并没有改善中长期临床结果中等活跃的UC.
- 需要进一步的研究来探索UC管理的替代或辅助疗法.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
402
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
402
Drugs for Treatment of Ulcerative Colitis in IBD
413
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
413
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
447
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
447
Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
435
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
435
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K


